Company intelligence / Profile preview

MBR

Toyonaka, Osaka, Japan

Ownership: Private
Development stage: Other

Overview

MBR is a private Japanese biotechnology company based in Toyonaka, Osaka. The company is described in business directories as developing cancer immunotherapeutic agents and programs related to tuberculosis and nontuberculous mycobacterial infections. Publicly available information on its pipeline, molecular targets, and specific product candidates appears limited. Based on the available evidence, MBR appears to be an active early-stage life sciences company rather than a commercial-stage pharmaceutical business.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cancer immunotherapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on MBR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBR.

Explore the full profile